He says the industry is willing to partner with payers to deliver outcomes-driven, sustainable healthcare, in pharmaphorum's magazine Deep Dive: Market Access.
Gilead Sciences, Johnson & Johnson, Novartis, Exelixis, and Pfizer have been taken to task by ICER for price increases without new clinical evidence.
In this issue, we delve into the transformative impact of AI on healthcare and pharma, featuring insights on key AI trends from the floor of Frontiers Health, the ongoing battle against drift, and
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl
IN THIS ISSUE: The 2024 US Presidential race is nearing its end, but what does that mean for pharma?
Launching a product is always an intense, pivotal moment, but in a fast moving era of scientific advances and regulatory change, it has become an even more critical enterprise.
In a new pharmaphorum podcast, editor-in-chief Jonah Comstock speaks with Dr Victoria Richon, CEO of Entact Bio, a company focused on the small molecule space, with its team of scientists,
This white paper is free and can be downloaded and read at your convenience
With nasal delivery systems offering faster absorption and non-invasive administration, they are becoming a cornerstone of modern therapeutics.
Unravelling Treg Biology, Pioneering Best-in-Class Approaches & Demonstrating Clinical Efficacy to Advance Validated Therapeutic Options in Autoimmunity, Inflammation & Beyond
